Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Insight Molecular Diagnostics Inc.

NASDAQ: IMDX · Life Sciences · 3 alerts · CIK 1642380

Share price
$1.86Close, Nov 16
Market cap
$60.9M
Shares outstanding
32.76MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Insight Molecular Diagnostics Inc. filings on SEC EDGAR ↗

4:06 PM ET 8-K
M&A Deal

Insight Molecular Diagnostics M&A Deal with Chronix Biomedical, Inc.

Insight Molecular Diagnostics (iMDx) entered into Amendment No. 2 to its merger agreement with Chronix, modifying the earnout structure related to the CNI Monitor technology. The amendment establishes that equity holders will receive a 10% royalty on sales until a potential sale of the technology occurs, at which point they will receive a final payment of 10% of the gross sale proceeds.

Counterparty
Chronix Biomedical, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.